#Lipid Nanoparticles Market

[healthcaremarketanalysis]

Lipid Nanoparticles Market to Reach USD 350.5M by 2029

The Global Lipid Nanoparticles Market is expected to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, with a CAGR of 5.2%, while the LNP services market is projected to rise from USD 135.5 million in 2024 to USD 238.1 million by 2029 at a CAGR of 11.9%. Growth is driven by advancements in LNP-based pharmaceuticals, particularly in anti-cancer and mRNA therapies, though regulatory challenges and formulation issues pose potential constraints. Key opportunities include the demand for advanced drug delivery systems and scalable mRNA vaccines. The market's key players include Avanti Polar Lipids, Merck KGaA, and FUJIFILM Pharmaceuticals, with North America being the leading regional market. The sector is influenced by diverse product segments such as ionizable and PEGylated lipids, with applications spanning COVID-19 and cancer treatments.

Download PDF Brochure

Browse in-depth TOC on "Lipid Nanoparticles Market"

398 - Tables

53 - Figures

316 - Pages

Factors Influencing Market Trends

The expansion of the lipid nanoparticles market is driven by increasing research and development efforts to create lipid nanoparticle-based drugs. However, stringent regulatory requirements may impede growth.

Product Segment Insights

The market is segmented by product into ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials, with ionizable lipids leading due to their crucial role in mRNA vaccines like Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273.

LNP Type Breakdown

Segmented into solid lipid nanoparticles, nanostructured lipid carriers, and other types, the solid lipid nanoparticles segment holds the largest share, favored for vaccine production and as an alternative drug delivery carrier.

Molecule Type Distribution

The market is divided by molecule type into siRNA, mRNA, and other molecules. The mRNA segment dominates due to its effectiveness in vaccine production and the enhanced delivery capabilities of lipid nanoparticles.

Application Areas

Segmented into commercial and clinical applications, the commercial segment currently holds the largest market share due to its extensive use in vaccine production. The clinical applications segment, however, is expected to grow the fastest, driven by advancements in targeted drug delivery and personalized medicine.

End-User Analysis for Raw Materials

For raw materials, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and CDMOs, with pharmaceutical & biotechnology companies holding the largest share due to their high use of lipid nanoparticles in drug development.

Service Type Analysis

The lipid nanoparticles services market, categorized into formulation development services, manufacturing services, and other services, sees the largest share in manufacturing services. This is driven by the high demand for raw materials and ongoing requirements from pharmaceutical and biotechnology companies.

End-User Analysis for Services

The services market is segmented by end users into pharmaceutical & biotechnology companies and academic & research institutes, with pharmaceutical & biotechnology companies leading due to their need for specialized manufacturing services and expertise.

Regional Market Overview

The lipid nanoparticles market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the largest share in 2023, benefiting from advanced healthcare infrastructure and significant R&D investments. However, the Asia Pacific region is anticipated to be the fastest-growing market during the forecast period, driven by increased healthcare expenditure, government initiatives, and favorable regulatory conditions.

Request Sample Pages

Growth Drivers and Challenges

The growth of the lipid nanoparticles market is driven by their increasing use in anti-cancer and RNA-based therapies. However, stringent regulatory requirements related to lipid nanoparticles may pose challenges to market expansion.

Market Consolidation

The lipid nanoparticles market is largely consolidated, with major players such as Avanti Polar Lipids (Croda International plc), Merck KGaA, NOF CORPORATION, and Nippon Fine Chemical holding 70-75% of the global market share.

Company Profiles

Avanti Polar Lipids (US): Established in 1967, Avanti specializes in high-purity lipids for biochemical and pharmaceutical research. The company offers a broad portfolio of lipid nanoparticles and custom synthesis services, heavily investing in R&D and collaborating with academic institutions to advance lipid formulations.

Merck KGaA (Germany): This healthcare and life sciences company provides a range of lipid nanoparticles products for research and clinical applications. Merck KGaA has strengthened its RNA production capabilities and recently acquired Exelead for approximately USD 780 million to enhance its CDMO services.

NOF CORPORATION (Japan): NOF CORPORATION is a prominent chemical manufacturer known for its lipid nanoparticle formulations. In April 2024, NOF collaborated with Phosphorex to provide lipid nanoparticles using their COATSOME® SA Series, which offers efficient nucleic acid delivery with minimal toxicity. NOF continues to innovate with high-purity lipid derivatives and liposome formulations for various drug applications.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets Inc.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA : 1-888-600-6441

UK +44-800-368-9399

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

[globalgrowthinsights]

Liposomal and Lipid Nanoparticle Drug Delivery Systems Market: Estimation, Potential, Development, Share, and Growth

""Liposomal and Lipid Nanoparticle Drug Delivery Systems Market""provides in-depth analysis on the market status of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market, including best facts and figures, overview, definition, SWOT analysis, expert opinions, and the most recent developments worldwide. The report also computes market size, Price, Revenue, Cost Structure, Gross Margin, Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Sales, and Market Share, Forecast and Growth Rate. The report helps to determine the revenue generated by the sale of this report and technologies across various application segments.

It is projected that between 2024 and 2032, The Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market would grow at a significant rate. In 2023, the market is likely to grow rapidly and over the estimated horizon due to the growing adoption of strategies by major players. This research provides a detailed analysis of the market size, characteristics, and growth of the Liposomal and Lipid Nanoparticle Drug Delivery Systems Market industry from 2024 to 2032. It is segmented based on the product type, downstream application, and consumption area of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market. Along with introducing industry participants from a value chain viewpoint, the research also examines the top businesses.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market in these regions till the forecast period

North America

Middle East and Africa

Asia-Pacific

South America

Europe

For more Click Here : https://www.globalgrowthinsights.com

Key Attentions of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Report:

The report offers a comprehensive and broad perspective on the global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market.

The market statistics represented in different Liposomal and Lipid Nanoparticle Drug Delivery Systems Market segments offers complete industry picture.

Market growth drivers, challenges affecting the development of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market are analyzed in detail.

The report will help in the analysis of major competitive market scenario, market dynamics of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market.

Major stakeholders, key companies Liposomal and Lipid Nanoparticle Drug Delivery Systems Market, investment feasibility and new market entrants study is offered.

Development scope of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market in each market segment is covered in this report. The macro and micro-economic factors affecting the Liposomal and Lipid Nanoparticle Drug Delivery Systems Market

Advancement is elaborated in this report. The upstream and downstream components of Liposomal and Lipid Nanoparticle Drug Delivery Systems Market and a comprehensive value chain are explained.

Browse More Details On This Report at:-  https://www.globalgrowthinsights.com/market-reports/liposomal-and-lipid-nanoparticle-drug-delivery-systems-market-101460

Global Growth Insights

Phone:

  US: +1 (888) 690-5999    UK: +44 8083 023308

Email: sales@globalgrowthinsights.com

[reasonsforhope]

"Engineers at the University of Pennsylvania have made a critical breakthrough that promises better outcomes for pregnancies threatened with pre-eclampsia, a condition that arises due to insufficient blood flow to the placenta, resulting in high maternal blood pressure and restricted blood flow to the fetus.

Pre-eclampsia is one of the leading causes of stillbirths and prematurity worldwide, and it occurs in 3 to 5% of pregnancies. Without a cure, options for these patients only treat symptoms, such as taking blood pressure medication, being on bed rest, or delivering prematurely—regardless of the viability of their baby.

Making a decision to treat pre-eclampsia in any manner can be a moral conundrum, to balance many personal health decisions with long-standing impacts—and for Kelsey Swingle, a doctoral student in the UPenn bioengineering lab, these options are not enough.

In previous research, she conducted a successful proof-of-concept study that examined a library of lipid nanoparticles (LNPs)—which are the delivery molecules that helped get the mRNA of the COVID vaccine into cells—and their ability to reach the placenta in pregnant mice.

In her latest study, published in Nature, Swingle examined 98 different LNPs and their ability to get to the placenta and decrease high blood pressure and increase vasodilation in pre-eclamptic pregnant mice.

Her work shows that the best LNP for the job was one that resulted in more than 100-fold greater mRNA delivery to the placenta in pregnant mice than an FDA-approved LNP formulation.

The drug worked.

“Our LNP was able to deliver an mRNA therapeutic that reduced maternal blood pressure through the end of gestation and improved fetal health and blood circulation in the placenta,” says Swingle.

“Additionally, at birth we saw an increase in litter weight of the pups, which indicates a healthy mom and healthy babies. I am very excited about this work and its current stage because it could offer a real treatment for pre-eclampsia in human patients in the very near future.”

While further developing this cure for pre-eclampsia and getting it to the market for human use is on the horizon for the research team, Swingle had to start from scratch to make this work possible. She first had to lay the groundwork to run experiments using pregnant mice and determine how to induce pre-eclampsia in this animal model, processes that are not as well studied.

But, by laying this groundwork, Swingle’s work has not only identified an avenue for curing pre-eclampsia, it also opens doors for research on LNP-mRNA therapeutics addressing other reproductive health challenges...

As Swingle thinks ahead for next steps in her research, which was funded by the National Institutes of Health and the National Science Foundation, she will also collaborate to further optimize the LNP to deliver the mRNA even more efficiently, as well as understanding the mechanisms of how it gets to the placenta, a question still not fully answered.

They are already in talks about creating a spin-off company and want to work on bringing this LNP-mRNA therapeutic to clinical trials and the market.

Swingle, who is currently finishing up her Ph.D. research, has not only successfully led this new series of studies advancing pre-eclampsia treatment at Penn, she has also inspired other early career researchers in the field as she continues to thrive while bringing women’s health into the spotlight."

-via Good News Network, December 15, 2024

[darkmaga-returns]

10 shocking stories the media buried today.

The Vigilant Fox

Dec 02, 2024

10 - A New Study Calls for an Immediate Halt to COVID-19 mRNA Injections

“A moratorium on the use of Pfizer/BioNTech COVID-19 vaccines and boosters should be enacted at minimum, but ideally, they should be REMOVED from the market, and their use in humans should be STOPPED.”

That’s the conclusion of a study published in the Journal of American Physicians and Surgeons. The report reveals glaring flaws and alarming safety concerns surrounding Pfizer/BioNTech’s COVID-19 injections.

Here’s a breakdown of the study’s key points, as shared by epidemiologist 

Nicolas Hulscher, MPH

:

1.) COVID-19 modRNA vaccines were labeled as traditional vaccines instead of gene therapy products, allowing them to skip stricter regulatory oversight.

2.) The spike protein produced by these vaccines is toxic and linked to immune-related complications.

3.) Pfizer’s own data shows lipid nanoparticles (LNPs) and modRNA spreading throughout the body—including the liver, spleen, ovaries, and adrenal glands.

4.) Spike protein production wasn’t limited to the injection site, contradicting early claims.

5.) Within just three months of rollout, Pfizer’s post-authorization data revealed 1,223 deaths and a flood of serious adverse events.

6.) Reports of adverse events after COVID-19 vaccines skyrocketed, far surpassing those for any prior vaccine, yet no significant action was taken.

As such, 

Nicolas Hulscher, MPH

 says:

“Using mRNA to hijack cells in various organ systems to produce a highly toxic [spike] protein that persists in the body for months to years was one of the worst ideas in human history.”

Follow 

Nicolas Hulscher, MPH

 and 

Peter A. McCullough, MD, MPH

 for more details on this study and breaking news about the COVID-19 injections.

Courageous Discourse™ with Dr. Peter McCullough & John Leake

BREAKING - New Study Demands Immediate Moratorium on COVID-19 mRNA Injections

By Nicolas Hulscher, MPH…

Read more

2 days ago · 425 likes · 89 comments · Nicolas Hulscher, MPH

(See 9 More Revealing Stories Below)

9 - One of the best supercuts ever exposes nine minutes of Democrats saying President Biden won't pardon Hunter because Joe Biden is a man of great character!

Great job making this, @Mazemoore.

8 - The View’s Sunny Hostin Is Forced to Read Another Legal Notice Live on Air

She’s literally dying inside as she reads this:

“Pete Hegseth has denied any wrongdoing. His lawyer said he paid the woman in 2023 to head off the threat of a baseless lawsuit. No charges were ever brought.”

This moment came after The View panel smeared Hegseth for two minutes straight.

7 - Scott Jennings Shuts Down CNN Panelist Trying to Blame Trump for Biden Pardoning Hunter

This is the mic drop moment of the day.

“We are sitting on the biggest cover-up of who knows what crimes, and Biden knows exactly when it started. He’s leaving office in disgrace—a liar. There’s no spinning this. It has nothing to do with Trump and everything to do with the character of Joe Biden.”

“You guys can spend all day long trying to spin this, that this is Donald Trump’s fault... These people are liars. ‘Inflation is transitory. Afghanistan, it’s a success. The border is secure. Robert Hur is a liar. The videos are cheap fakes. Biden has a cold. He’ll never drop out. Oh, I’ll never pardon Hunter.’ It’s all a lie. It is all a grift. Every American except the most partisan, brain-rotted people are going to be outraged by this.”

“Joe Biden, Karine Jean-Pierre—how many minutes of tape do we have of both of these people telling the American people this will not happen?... If Karine Jean-Pierre had an ounce of self-respect, she’d get off the plane in Africa today where they’re going so he can avoid the press and resign.”

6 - CNN ADMITTED Biden pardoned Hunter for ALL crimes for the past 11 years out of fear that his family would be investigated by the Trump administration

“But there was a worry [about] future prosecutions or future the potential of what the incoming Trump Justice Department could do. So that, of course, is fretted in all of this as well.”

Credit: https://x.com/nicksortor/status/1863407436306014431

While you’re here, don’t forget to subscribe to this page for more daily news roundups.Subscribe

#5 - Special Counsel Rejects Hunter Biden’s Pardon, Files Scathing Rebuke in Court

#4 - Former CNN Lefty Crank John Harwood Gets Embarrassing Community Note on 𝕏

#3 - Liberal Pollster Loses His Mind Over Hunter Biden Pardon

#2 - John Bolton Unhappy with Trump’s Kash Patel Pick, JD Vance Responds with Fire

#1 - A congressional subcommittee concluded its two-year investigation on the coronavirus pandemic today, finding that COVID-19 likely originated from a lab in Wuhan, China and that social distancing and masking were not backed with scientific data.

"During closed-door testimony, Dr. [Anthony] Fauci testified that the guidance ‘sort of just appeared,’" the report states.

The subcommittee also found "no conclusive evidence" that wearing masks protected Americans from COVID-19.

Read More: https://www.foxnews.com/politics/covid-most-likely-leaked-from-wuhan-lab-social-distancing-not-based-science-select-committee-finds

BONUS #1 - Whoopi Goldberg Goes Crazy Defending Hunter’s Pardon, Demands Co-Host Stop Calling Biden a Liar

BONUS #2 - The Shocking Truth About Skin Cancer: What You’re Not Being Told About the Sun

BONUS #3 - 11 Surprising Ways Vitamin C Boosts Your Health

BONUS #4 - How to Get Ivermectin, Z-Pak and More

BONUS #5 - Why You Should Never Touch Receipts

[liesmyteachertoldme]

New Study Demands Immediate Moratorium on COVID-19 mRNA Injections

Regulatory Classification and Guidelines:

COVID-19 modRNA vaccines were misclassified as traditional vaccines rather than gene therapy products, bypassing stricter regulatory requirements.

WHO guidelines from 2005 were used for nonclinical assessments, despite being outdated and inapplicable to modRNA vaccines.

Spike Protein and Safety Concerns:

The spike protein produced by modRNA vaccines is toxic and can cause immune-related complications.

Studies on pharmacokinetics (how much spike protein is produced, where it distributes, and how long it persists) were not conducted as part of Pfizer’s submission.

Spike protein production varies among individuals based on genetics, health status, and other factors, but this variability was never studied.

Biodistribution and LNP Behavior:

Pfizer’s own biodistribution data showed lipid nanoparticles (LNPs) and modRNA were widely distributed throughout the body, including the liver, spleen, ovaries, and adrenal glands.

Contrary to claims, spike protein production was not limited to the injection site, raising concerns about off-target effects and toxicity.

Toxicology and Carcinogenicity Testing:

Pfizer did not conduct genotoxicity or carcinogenicity studies, despite the potential for the spike protein and LNPs to cause harm.

Wistar Han™ rats, which are not a relevant species for SARS-CoV-2 toxicity studies, were used inappropriately in preclinical testing.

Deficient Clinical Trials:

Phase I clinical trials failed to measure critical factors like the amount and variability of spike protein produced in individuals.

Placebo groups in initial trials were unblinded early, undermining the integrity of long-term safety and efficacy data.

Adverse Events and VAERS Reporting:

Post-authorization data from Pfizer showed 1,223 deaths and numerous serious adverse events within the first three months of vaccine rollout.

The Vaccine Adverse Event Reporting System (VAERS) documented a huge spike in reported adverse events following the COVID-19 vaccine rollout, far exceeding reports for previous vaccines.

Despite the massive increase in reported deaths and injuries, no corrective actions were taken. This contrasts with earlier vaccines like Rotashield®, which were removed after only 15 cases of intussusception.

Regulatory Oversight Failures:

The FDA and other global regulatory agencies overlooked or dismissed major concerns raised during the review process.

Regulatory assessments relied on insufficient data and assumptions rather than rigorous scientific evidence.

Call for a Moratorium:

Based on incomplete data, serious safety concerns, and potential long-term risks, the authors recommend a moratorium on Pfizer/BioNTech’s COVID-19 modRNA vaccines.

Proper studies must be conducted to ensure safety, as the responsibility lies with the pharmaceutical industry, not independent scientists.

Since the proper conditions for market withdrawal have been met, the primary obstacle preventing an immediate moratorium on COVID-19 genetic injections is our captured regulatory agencies, which will hopefully be dealt with after the Senate confirmation process.

[health-views-updates]

Comprehensive Outlook on Antisense and RNAi Therapeutics Market Growth & Trends 2024-2032

The Antisense and RNAi Therapeutics Market Revenue is projected to reach USD 18.48 billion by 2032, growing at an impressive CAGR of 18.05% over the forecast period from 2024 to 2032. The market growth is being driven by the increasing adoption of gene-silencing technologies such as antisense oligonucleotides (ASOs) and RNA interference (RNAi) for the treatment of a wide range of diseases, including genetic disorders, cancer, and viral infections.

Key Market Drivers

Antisense and RNAi therapeutics are gaining significant traction in the pharmaceutical industry due to their ability to specifically target and modulate gene expression. These therapies are proving to be highly effective in treating diseases that have been traditionally difficult to address, including various types of cancers, rare genetic diseases, and viral infections.

One of the main factors driving the growth of the antisense and RNAi therapeutics market is the expanding pipeline of RNA-targeted drugs. Numerous clinical trials are currently underway, testing the efficacy of these innovative therapies for a variety of conditions. The success of drugs like Spinraza (for spinal muscular atrophy) and Onpattro (for hereditary transthyretin amyloidosis) has significantly raised the profile of RNA-based therapeutics, fostering greater investment in this area.

Moreover, the growing demand for personalized medicine, which focuses on tailoring treatments based on an individual's genetic profile, is boosting the adoption of gene-silencing technologies. RNA therapies are highly personalized, offering the potential for precision treatments that can target the root cause of diseases at a molecular level.

Advances in RNA Technologies

Technological advancements in RNA delivery systems and improved understanding of RNA biology are further contributing to the growth of the market. Over the past decade, there have been significant breakthroughs in optimizing RNA-based therapies, particularly in improving the stability, specificity, and delivery of RNA molecules to target cells.

The development of lipid nanoparticles (LNPs) for RNA delivery has been a key innovation that has enabled the success of several RNA-based vaccines and therapeutics, such as those used for COVID-19. These advancements are being applied to antisense and RNAi therapies, enhancing their potential to treat a wide range of diseases.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/4493

Regional Insights

North America holds a dominant position in the antisense and RNAi therapeutics market due to the presence of leading biotechnology and pharmaceutical companies, robust healthcare infrastructure, and favorable government initiatives supporting RNA-based research. The U.S. Food and Drug Administration (FDA) has been particularly active in approving RNA-targeted therapies, providing a boost to the market in the region.

The Asia-Pacific region is expected to witness significant growth during the forecast period, driven by increasing investments in biotechnology research and the rising prevalence of genetic disorders and cancer. Governments in countries like China and India are making substantial investments in healthcare innovation, which will likely drive the adoption of antisense and RNAi therapeutics.

Future Outlook

The antisense and RNAi therapeutics market is poised for robust growth in the coming years, with increasing clinical success stories and the continued expansion of RNA-targeted therapies. As more drugs gain regulatory approval and enter the market, the potential for antisense and RNAi therapeutics to revolutionize the treatment landscape for a variety of diseases will continue to expand.

In addition, the growing number of strategic collaborations between pharmaceutical companies, academic institutions, and research organizations is expected to accelerate the development of new RNA-based therapies. These partnerships are fostering innovation and advancing the understanding of RNA-targeted treatments, further driving market growth.

The ability of antisense and RNAi therapeutics to treat rare and previously untreatable conditions makes them an attractive investment opportunity for both public and private sectors. With the expanding applications and increasing demand for personalized medicine, the antisense and RNAi therapeutics market is set to witness significant innovation and growth in the coming years.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us

Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[shubhampawrainfinium]

Beauty Revolutionized: Harnessing Nanotechnology for Next-Gen Cosmetics

The global nanotechnology in cosmetics market is poised for significant growth over the forecast period from 2022 to 2028, driven by the rising demand for advanced, effective, and innovative cosmetic products. The incorporation of nanotechnology in cosmetic formulations is gaining immense popularity, as it represents one of the most cutting-edge and rapidly advancing technologies in the sector. This approach has opened new avenues in product development, enhancing efficacy and user experience across skincare, haircare, makeup, and anti-aging products.

What is Nanotechnology in Cosmetics?

Nanotechnology in cosmetics involves using nanoparticles to improve the delivery, stability, and effectiveness of active ingredients. By reducing ingredient particles to nano-sized units, the technology allows for deeper skin penetration, increased stability, and longer-lasting effects. Types of nanotechnology applications in cosmetics include:

Nanocapsules: These are small vesicles that encapsulate active ingredients, improving targeted delivery to the skin.

Liposomes: Microscopic bubbles that carry moisturizing and active agents deep into the skin.

Nanoemulsions: Fine, stable emulsions that enhance texture and sensory properties in cosmetics.

Solid Lipid Nanoparticles (SLNs): These provide controlled release and protect active ingredients from degradation.

Get Sample pages of Report: https://www.infiniumglobalresearch.com/reports/sample-request/41182

Market Dynamics and Growth Drivers

Several factors are propelling the growth of nanotechnology in the cosmetics market:

Growing Demand for Anti-Aging and Skin Care Products: With an aging global population and a rising focus on skincare, there is a high demand for products that offer visible and lasting effects. Nanotechnology enhances the performance of active ingredients, making anti-aging creams, sunscreens, and moisturizers more effective.

Increased Awareness of Advanced Beauty Solutions: Consumers are becoming more knowledgeable about skincare science, showing a preference for products that offer innovative solutions. The appeal of nano-based products lies in their effectiveness, safety, and ability to provide enhanced benefits compared to traditional formulations.

Technological Advancements and R&D Investments: Continuous research and development efforts have led to the introduction of innovative nano-ingredients. As cosmetic companies invest in nanotechnology to develop unique formulations, the market benefits from increased product variety and advancements in cosmetic science.

Rising Consumer Awareness and Demand for Premium Products: With growing consumer awareness about skin health and the efficacy of nano-based solutions, there is a heightened demand for premium products that deliver superior performance. This trend is driving the demand for nano-based products in the luxury cosmetics segment.

Regional Analysis

North America: North America is a major market for nanotechnology in cosmetics, with a high demand for advanced beauty products. The region's robust R&D landscape and early adoption of innovative technologies support market growth.

Europe: Europe is a prominent market due to the presence of key cosmetics brands and the increasing emphasis on product efficacy and safety. European consumers have a strong preference for high-quality skincare products, which drives the demand for nano-enhanced cosmetics.

Asia-Pacific: The Asia-Pacific region is expected to exhibit the highest growth rate, supported by rising disposable incomes, a growing beauty-conscious population, and increased awareness of advanced cosmetic formulations. Markets like South Korea, Japan, and China are key contributors to this growth.

Latin America and Middle East & Africa: These regions are gradually adopting nanotechnology in cosmetics, driven by increased urbanization and awareness of skincare advancements. Growth in these areas is anticipated as consumers seek products with higher efficacy.

Competitive Landscape

The nanotechnology in cosmetics market is characterized by both established and emerging players who are focusing on product innovation and expansion to meet consumer demands. Some key companies include:

L’Oréal: A pioneer in nanotechnology in cosmetics, L'Oréal invests heavily in R&D and has introduced several nano-based skincare and haircare products. The company's commitment to innovation strengthens its market position.

Procter & Gamble: Known for its broad cosmetics portfolio, Procter & Gamble incorporates nanotechnology in select premium products, enhancing product efficacy and performance.

Unilever: With a range of popular skincare and personal care brands, Unilever leverages nanotechnology to improve the performance and user experience of its products, particularly in skincare.

Shiseido: This Japanese beauty giant is an early adopter of nanotechnology, using nano-emulsions and delivery systems in its high-end products to enhance skin benefits.

Estée Lauder: Estée Lauder’s premium skincare products utilize nanotechnology to enhance penetration and deliver targeted skincare benefits, especially in its anti-aging range.

Report Overview : https://www.infiniumglobalresearch.com/reports/global-nanotechnology-in-cosmetics-market

Challenges and Opportunities

While the outlook for nanotechnology in cosmetics is promising, the market faces challenges such as regulatory scrutiny and consumer concerns about the safety of nanoparticles. Governments and health organizations are implementing regulations to ensure the safety of nano-ingredients, which can influence the pace of new product launches.

However, opportunities abound as awareness of nanotechnology’s benefits continues to grow. The demand for premium and effective products is driving investment in new applications, including nano-formulated sunscreens, anti-aging creams, and haircare products. The growing emphasis on sustainable and clean beauty also presents opportunities for companies to develop eco-friendly nano-solutions.

Conclusion

The nanotechnology in cosmetics market is expected to grow significantly over the forecast period, driven by advancements in skincare science, consumer demand for effective products, and the benefits nanotechnology offers in enhancing product performance. As innovation and investment continue, nanotechnology is set to reshape the cosmetics landscape, creating new opportunities for growth and product development across the skincare and beauty industry.

Bottom of Form

Discover More of Our Reports

United States Process Instrumentation Market

Vietnam Fresh Food Packaging Market

[decentralvaccine]

Northwestern University Sues Moderna Over Patented Covid 19 Vaccine Technology

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid nanoparticles to develop its SpikeVax COVID-19 vaccine.

NU had a critical role in the development of the lipid nanoparticles, according to the complaint. The University also argued Moderna’s explicit use of the particles in its mRNA vaccine was a violation of the patent. The University is seeking “reasonable royalties” but did not specify how much money it expects from Moderna.

Moderna’s SpikeVax was first introduced to the market in December 2020. Last year, the company earned $6.7 billion in revenue from the vaccine.

https://dailynorthwestern.com/2024/10/22/campus/northwestern-files-lawsuit-against-moderna-seeks-royalties-for-covid-mrna-vaccine-technology/

[healthcaremarketanalysis]

Lipid Nanoparticles Market to Reach USD 350.5M by 2029

The Global Lipid Nanoparticles Market is expected to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, with a CAGR of 5.2%, while the LNP services market is projected to rise from USD 135.5 million in 2024 to USD 238.1 million by 2029 at a CAGR of 11.9%. Growth is driven by advancements in LNP-based pharmaceuticals, particularly in anti-cancer and mRNA therapies, though regulatory challenges and formulation issues pose potential constraints. Key opportunities include the demand for advanced drug delivery systems and scalable mRNA vaccines. The market's key players include Avanti Polar Lipids, Merck KGaA, and FUJIFILM Pharmaceuticals, with North America being the leading regional market. The sector is influenced by diverse product segments such as ionizable and PEGylated lipids, with applications spanning COVID-19 and cancer treatments.

Download PDF Brochure

Browse in-depth TOC on "Lipid Nanoparticles Market"

398 - Tables

53 - Figures

316 - Pages

Factors Influencing Market Trends

The expansion of the lipid nanoparticles market is driven by increasing research and development efforts to create lipid nanoparticle-based drugs. However, stringent regulatory requirements may impede growth.

Product Segment Insights

The market is segmented by product into ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials, with ionizable lipids leading due to their crucial role in mRNA vaccines like Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273.

LNP Type Breakdown

Segmented into solid lipid nanoparticles, nanostructured lipid carriers, and other types, the solid lipid nanoparticles segment holds the largest share, favored for vaccine production and as an alternative drug delivery carrier.

Molecule Type Distribution

The market is divided by molecule type into siRNA, mRNA, and other molecules. The mRNA segment dominates due to its effectiveness in vaccine production and the enhanced delivery capabilities of lipid nanoparticles.

Application Areas

Segmented into commercial and clinical applications, the commercial segment currently holds the largest market share due to its extensive use in vaccine production. The clinical applications segment, however, is expected to grow the fastest, driven by advancements in targeted drug delivery and personalized medicine.

End-User Analysis for Raw Materials

For raw materials, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and CDMOs, with pharmaceutical & biotechnology companies holding the largest share due to their high use of lipid nanoparticles in drug development.

Service Type Analysis

The lipid nanoparticles services market, categorized into formulation development services, manufacturing services, and other services, sees the largest share in manufacturing services. This is driven by the high demand for raw materials and ongoing requirements from pharmaceutical and biotechnology companies.

End-User Analysis for Services

The services market is segmented by end users into pharmaceutical & biotechnology companies and academic & research institutes, with pharmaceutical & biotechnology companies leading due to their need for specialized manufacturing services and expertise.

Regional Market Overview

The lipid nanoparticles market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the largest share in 2023, benefiting from advanced healthcare infrastructure and significant R&D investments. However, the Asia Pacific region is anticipated to be the fastest-growing market during the forecast period, driven by increased healthcare expenditure, government initiatives, and favorable regulatory conditions.

Request Sample Pages

Growth Drivers and Challenges

The growth of the lipid nanoparticles market is driven by their increasing use in anti-cancer and RNA-based therapies. However, stringent regulatory requirements related to lipid nanoparticles may pose challenges to market expansion.

Market Consolidation

The lipid nanoparticles market is largely consolidated, with major players such as Avanti Polar Lipids (Croda International plc), Merck KGaA, NOF CORPORATION, and Nippon Fine Chemical holding 70-75% of the global market share.

Company Profiles

Avanti Polar Lipids (US): Established in 1967, Avanti specializes in high-purity lipids for biochemical and pharmaceutical research. The company offers a broad portfolio of lipid nanoparticles and custom synthesis services, heavily investing in R&D and collaborating with academic institutions to advance lipid formulations.

Merck KGaA (Germany): This healthcare and life sciences company provides a range of lipid nanoparticles products for research and clinical applications. Merck KGaA has strengthened its RNA production capabilities and recently acquired Exelead for approximately USD 780 million to enhance its CDMO services.

NOF CORPORATION (Japan): NOF CORPORATION is a prominent chemical manufacturer known for its lipid nanoparticle formulations. In April 2024, NOF collaborated with Phosphorex to provide lipid nanoparticles using their COATSOME® SA Series, which offers efficient nucleic acid delivery with minimal toxicity. NOF continues to innovate with high-purity lipid derivatives and liposome formulations for various drug applications.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets Inc.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA : 1-888-600-6441

UK +44-800-368-9399

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

[colinwilson11]

The Non-Viral Drug Delivery Systems Market To Grow Owing To Increasing Advantages Over Viral Delivery Methods

Non-viral drug delivery systems have gained immense popularity in recent years owing to their advantages over viral delivery methods including low immunogenicity, larger transgene capacity and ease of production. Non-viral techniques involve encapsulating drugs into nanoparticles, liposomes or conjugating them to targeting moieties and are generally considered safer than viral vectors.

The Non-Viral Drug Delivery Systems Market is estimated to be valued at US$ 8.1 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the non-viral drug delivery systems market are Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, eTheRNA Immunotherapies. The companies are investing heavily in R&D to develop novel non-viral vectors with higher efficiency and safety. The growing demand for targeted drug delivery systems is a major factor driving the non-viral drug delivery systems market. Non-invasive therapeutic delivery through oral, transdermal and inhalation routes has gained prominence. Technological advancements like lipid nanoparticles, polymeric nanoparticles and conjugation with cell-penetrating peptides have increased the delivery of macromolecules.

Market Trends

One of the major trends in the non-viral drug delivery systems market is the rising focus on gene therapy. Non-viral gene delivery methods offer less immunogenic and inflammatory responses making them safer for repeated administration. mRNA-based therapies and applications in cancer immunotherapy are emerging as lucrative opportunities. Another key trend is the development of stimuli-responsive delivery systems that are designed to release drug payloads in response to specific biochemical cues like pH, redox potential or enzymatic activity at the site of action.

Market Opportunities

Targeted delivery to tumors using actively/passively targeted nanoparticles presents a huge opportunity. The application of nanotechnology has allowed efficient delivery of anti-cancer drugs, imaging agents and nucleic acids selectively to tumor tissues. Oligonucleotide therapeutics also offer lucrative opportunities given the advances in mRNA vaccines. Non-invasive delivery through pulmonary route for treatment of lung cancers and respiratory diseases is an emerging area of focus.

Impact Of COVID-19 On Non-Viral Drug Delivery Systems Market Growth

The COVID-19 pandemic has significantly impacted the non-viral drug delivery systems market. During the initial phases of the pandemic, most non-essential research was put on hold or delayed, impacting the development of new drug delivery technologies. Companies focused their efforts on developing COVID-19 vaccines and therapeutics to address the urgent medical need. This diverted resources away from other drug delivery applications.

However, as the pandemic progressed, companies recognized the long-term market potential for non-viral delivery platforms to address future pandemics and other diseases. Nanoparticle-based delivery systems can effectively transport mRNA, DNA and protein therapeutics into cells, making them well-suited for developing new classes of antiviral drugs and vaccines. Several companies utilized their non-viral platforms to design COVID-19 vaccines and therapies during clinical trials.

Going forward, governments and healthcare agencies are expected to prioritize research into development capabilities for rapid responses to health emergencies. Non-viral delivery technologies can play a major role here through their ability to package different types of biologics and enable faster discovery processes compared to viral vectors. Companies are also advancing formulations tuned for stability at varying temperatures and extended shelf-life to address logistical challenges in vaccine distribution globally.

North America Dominates Non-Viral Drug Delivery Systems Market

The North America region currently dominates the Non-Viral Drug Delivery Systems Market in terms of value. This is due to presence of established pharmaceutical and biotechnology companies engaged in development and commercialization of delivery platforms for various biologics. Large companies have made significant investments setting up research centers focused on non-viral technologies.

Government funding for innovation is also strong through the National Institute of Health and Department of Defense programs. Academic research is rapidly advancing new formulations and delivery routes. The U.S. and Canada also have a well-developed regulatory system to approve new drug-device combination products incorporating non-viral carriers. High healthcare spends per capita contribute to faster market uptake of advanced therapeutics enabled by these platforms.

Asia Pacific Emerging As Fastest Growing Region

Going forward, the Asia Pacific region is expected to offer the fastest market growth opportunities for non-viral drug delivery systems. This is attributable to rising chronic disease prevalence in highly populated countries like China and India. Governments are investing significantly to build local R&D capabilities through initiatives such as the Made in China 2025 policy.

Countries like South Korea and Japan also have large biotechnology industries focusing on formulations. At the same time, reduced manufacturing and labor costs are attracting global pharmaceutical companies to outsource production to Asia Pacific contract development and manufacturing organizations. This will help expand regional production capacities for various non-viral technologies.

Get more insights on this topic:  https://www.ukwebwire.com/non-viral-drug-delivery-systems-market-are-estimated-to-witness-high-growth-owing-to-advancements-in-nanotechnology/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

What Are The Key Data Covered In This Non-Viral Drug Delivery Systems Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Non-Viral Drug Delivery Systems Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Non-Viral Drug Delivery Systems Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Non-Viral Drug Delivery Systems Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Non-Viral Drug Delivery Systems Market vendors

FAQ’s

Q.1 What are the main factors influencing the Non-Viral Drug Delivery Systems Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Non-Viral Drug Delivery Systems Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Non-Viral Drug Delivery Systems Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[thealphareporter]

Lipid Nanoparticles (LNPs) CDMO Market Analysis: Key Developments and Growth Projections

http://dlvr.it/TCtVtK

[newsheadlinesnow]

Lipid Nanoparticles (LNPs) CDMO Market Analysis: Key Developments and Growth Projections

http://dlvr.it/TCtTrd

[darkmaga-returns]

Source: HarveyRisch

“A moratorium on the use of Pfizer/BioNTech COVID-19 vaccines and boosters should be enacted at minimum, but ideally, they should be REMOVED from the market, and their use in humans should be STOPPED.”

That’s the conclusion of a study published in the Journal of American Physicians and Surgeons. The report reveals glaring flaws and alarming safety concerns surrounding Pfizer/BioNTech’s COVID-19 injections.

Here’s a breakdown of the study’s key points, as shared by epidemiologist Nicolas Hulscher, MPH:

1.) COVID-19 modRNA vaccines were labeled as traditional vaccines instead of gene therapy products, allowing them to skip stricter regulatory oversight.

2.) The spike protein produced by these vaccines is toxic and linked to immune-related complications.

3.) Pfizer’s own data shows lipid nanoparticles (LNPs) and modRNA spreading throughout the body—including the liver, spleen, ovaries, and adrenal glands.

4.) Spike protein production wasn’t limited to the injection site, contradicting early claims.

5.) Within just three months of rollout, Pfizer’s post-authorization data revealed 1,223 deaths and a flood of serious adverse events.

6.) Reports of adverse events after COVID-19 vaccines skyrocketed, far surpassing those for any prior vaccine, yet no significant action was taken.